Compare OGN & GRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OGN | GRDN |
|---|---|---|
| Founded | 1923 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Retail-Drug Stores and Proprietary Stores |
| Sector | Health Care | Consumer Staples |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.7B |
| IPO Year | N/A | 2024 |
| Metric | OGN | GRDN |
|---|---|---|
| Price | $8.78 | $26.92 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 3 |
| Target Price | $14.10 | ★ $33.33 |
| AVG Volume (30 Days) | ★ 5.3M | 291.7K |
| Earning Date | 02-12-2026 | 11-10-2025 |
| Dividend Yield | ★ 0.91% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.91 | 0.28 |
| Revenue | ★ $6,301,000,000.00 | $1,389,638,000.00 |
| Revenue This Year | N/A | $19.50 |
| Revenue Next Year | N/A | $0.48 |
| P/E Ratio | ★ $4.58 | $96.96 |
| Revenue Growth | N/A | ★ 18.68 |
| 52 Week Low | $6.18 | $17.78 |
| 52 Week High | $17.23 | $37.43 |
| Indicator | OGN | GRDN |
|---|---|---|
| Relative Strength Index (RSI) | 75.89 | 32.27 |
| Support Level | $8.17 | $30.17 |
| Resistance Level | $8.49 | $31.90 |
| Average True Range (ATR) | 0.36 | 1.42 |
| MACD | 0.15 | -0.38 |
| Stochastic Oscillator | 98.60 | 0.40 |
Organon & Co is a science-based pharmaceutical company that develops and delivers health solutions through a portfolio of prescription therapies within women's health, biosimilars, and established brands. The Company's operations include the following product portfolio: Women's health, Biosimilars and Established medicines. Geographically, it derives a majority of its revenue from Europe and Canada followed by the United States and then Asia Pacific and Japan. The company generates the majority of its revenue from the Established Brands product portfolio.
Guardian Pharmacy Services Inc is a differentiated pharmacy services company that provides an extensive suite of technology-enabled services designed to help residents of LTCFs adhere to their appropriate drug regimen, which in turn helps reduce the cost of care and improve clinical outcomes. The company emphasizes high-touch, individualized clinical, drug dispensing, and administration capabilities that are tailored to serve the needs of residents in historically lower acuity LTCFs, such as ALFs and BHFs. The operating segment derives its revenues through sales of pharmaceutical and medical products, and all revenues are derived solely in the United States.